loading...| Preferred Name |
Crizotinib |
|
| Synonyms |
|
|
| Definitions |
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C74061 |
|
| Accepted_Therapeutic_Use_For |
Non-Small Cell Lung Cancer; inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). |
|
| ALT_DEFINITION |
A substance being studied in the treatment of some types of cancer. It blocks enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. |
|
| CAS_Registry |
877399-52-5 |
|
| CHEBI_ID |
CHEBI:64310 |
|
| Chemical_Formula |
C21H22Cl2FN5O |
|
| code |
C74061 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. |
|
| Display_Name |
Crizotinib |
|
| FDA_UNII_Code |
53AH36668S |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Crizotinib |
|
| Legacy Concept Name |
MET_Tyrosine_Kinase_Inhibitor_PF-02341066 |
|
| Maps_To |
Crizotinib |
|
| NCI_Drug_Dictionary_ID |
586080 |
|
| PDQ_Closed_Trial_Search_ID |
586080 |
|
| PDQ_Open_Trial_Search_ID |
586080 |
|
| Preferred_Name |
Crizotinib |
|
| prefixIRI |
NCIT:C74061 |
|
| prefLabel |
Crizotinib |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2974289 |
|
| subClassOf |
http://purl.obolibrary.org/obo/NCIT_C143099 |